» Articles » PMID: 33767954

Neuro-ophthalmic Manifestations of Mitochondrial Disorders and Their Management

Overview
Specialty Ophthalmology
Date 2021 Mar 26
PMID 33767954
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The visual system has high metabolic requirements and is therefore particularly vulnerable to mitochondrial dysfunction. The most commonly affected tissues include the extraocular muscles, photoreceptors, retinal pigment epithelium, optic nerve and visual cortex. Hence, the most common manifestations of mitochondrial disorders are progressive external ophthalmoplegia, macular pattern dystrophy, pigmentary retinopathy, optic neuropathy and retrochiasmal visual field loss. With the exception of Leber hereditary optic neuropathy and stroke-like episodes seen in mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, the majority of neuro-ophthalmic manifestations have an insidious onset. As such, some patients may not recognize subtle progressive visual symptoms. When mitochondrial disorders are highly suspected, meticulous examination performed by an ophthalmologist with targeted ancillary testing can help confirm the diagnosis. Similarly, neuro-ophthalmic symptoms and signs may be the first indication of mitochondrial disease and should prompt systemic investigations for potentially life-threatening associations, such as cardiac conduction defects. Finally, the ophthalmologist can offer symptomatic treatments for some of the most disabling manifestations of these disorders.

Citing Articles

Photobiomodulation in ocular therapy: current status and future perspectives.

Chichan H, Aldujaly I, Michalakis K, Kanal L Int J Ophthalmol. 2025; 18(2):351-357.

PMID: 39967973 PMC: 11754031. DOI: 10.18240/ijo.2025.02.20.


Photobiomodulation Using Light-Emitting Diode (LED) for Treatment of Retinal Diseases.

Siqueira R Clin Ophthalmol. 2024; 18:215-225.

PMID: 38283180 PMC: 10813238. DOI: 10.2147/OPTH.S441962.


Recent advances in mitochondrial diseases: From molecular insights to therapeutic perspectives.

Aldossary A, Tawfik E, Alomary M, Alsudir S, Alfahad A, Alshehri A Saudi Pharm J. 2022; 30(8):1065-1078.

PMID: 36164575 PMC: 9508646. DOI: 10.1016/j.jsps.2022.05.011.


The spectrum of neuro-ophthalmologic involvement in mitochondrial disorders is broad.

Finsterer J Taiwan J Ophthalmol. 2022; 11(4):425-426.

PMID: 35070678 PMC: 8757515. DOI: 10.4103/tjo.tjo_18_21.

References
1.
Shoffner J, Lott M, Lezza A, Seibel P, Ballinger S, Wallace D . Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell. 1990; 61(6):931-7. DOI: 10.1016/0092-8674(90)90059-n. View

2.
Guy J, Feuer W, Porciatti V, Schiffman J, Abukhalil F, Vandenbroucke R . Retinal ganglion cell dysfunction in asymptomatic G11778A: Leber hereditary optic neuropathy. Invest Ophthalmol Vis Sci. 2014; 55(2):841-8. PMC: 3920864. DOI: 10.1167/iovs.13-13365. View

3.
Klebe S, Depienne C, Gerber S, Challe G, Anheim M, Charles P . Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy. Brain. 2012; 135(Pt 10):2980-93. PMC: 3470714. DOI: 10.1093/brain/aws240. View

4.
Bucelli R, Lee M, McClelland C . Chronic Progressive External Ophthalmoplegia in the Absence of Ptosis. J Neuroophthalmol. 2016; 36(3):270-4. DOI: 10.1097/WNO.0000000000000384. View

5.
Meyerson C, Van Stavern G, McClelland C . Leber hereditary optic neuropathy: current perspectives. Clin Ophthalmol. 2015; 9:1165-76. PMC: 4492634. DOI: 10.2147/OPTH.S62021. View